|
Centreeurope.org |
||
The Polish pharmaceutical sector |
|
Arrival of Gierek on power in 1970 gave a true impulse to the Polish pharmaceutical
sector, before starting a slow decline, which reaches its paroxysm at the end
of the years 1980. Poland has then the significant medical problems, aspirine
starts to miss and the syringes are used several times, thus involving major risks
of contagion of AIDS and hepatitis. During the first years of the transition,
the foreign multinationals benefit from this situation to set up a company in
Poland and to stick the favours of the Polish doctors, who prescribe drugs on
that the population hasn't means. The generic products are for these reasons are
very snuffed. Since the beginning of the years 1990, the pharmaceutical sector in Poland considerably packed, supported by the domestic demand in rise and more recently by the consequences of the accession to the European Union. Poland suffers from a local tradition of the copy of drugs and very long access at the market, about ten years after obtaining the patent. Because of the high level of innovation and research and the development of the sector, the conditions of setting to the community standards with regard to in particular the respect of the intellectual property constituted a significant element of the arrival of the foreign investors. Poland obtained a limited period authorizing a derogatory regime until the end of 2008. The Polish pharmaceutical sector is concentrated, two thirds of the production were realized by the ten principal actors. The principal actors are Servier Polska, GlaxoSmithkline and Polpharma. An about sixty licensed drugs are foreign product. Polish pharmaceutical industry provides approximately 80 % of the consumed drugs in Poland. Handicapped by the low number of laboratories of research, Poland produces primarily generic drugs. Poland is not a large exporter of pharmaceutical products. The countries of central and eastern Europe are the principal consumer, with at the head Russia, followed by Lithuania and Ukraine. The firms having made object of partial
or total privatization are the firms of the group of State Polfa which was divided
into smaller unities. Since 1994 several formulas of privatization were used with
the marketings of the societies by sale of action dimensioned with Warsaw Stock
Exchange, like the firms Polfa Kutno and Polfa Jelfa, the purchase of the unities
by a foreign or domestic investor (e.g. Polfa Poznan, Glaxo Smithkline), the purchase
by the However the privatization is not completely completed, which should mark the arrival of new foreign investors. |
IMPORTANT ! The current version of Centreeurope.org is not fully updated anymore. A new version with thousands of pages about Central and Eastern European countries will be launched soon. Please check our new websites for Central and Eastern Europe countries |